Drug Update · Neurology

FDA Approves Efgartigimod for gMG: 67.7% MG-ADL Response

August 09, 2026

MG-ADL responder rate (Study 1, anti‑AChR+)

67.7% vs 29.7% with placebo [11]

QMG responder rate (Study 1, anti‑AChR+)

63.1% vs 14.1% with placebo [11]

Study 1 enrollment

167 patients randomized (EFG IV n=84; placebo n=83) [11]

Approved subcutaneous dose

Prefilled syringe 1,000 mg efgartigimod + 10,000 units hyaluronidase once weekly ×4 per cycle (vial: 1,008 mg / 11,200 units) [11]

Clinical Perspective

This approval affects neurologists and clinicians managing adult patients with generalized myasthenia gravis, particularly those with anti‑AChR antibody positivity, by adding an FDA‑approved subcutaneous FcRn blocker to the therapeutic armamentarium ^[2]. The trial data support use of efgartigimod to achieve MG-ADL and QMG responses versus placebo in anti‑AChR antibody–positive patients, and the approved SC coformulation provides a weekly ×4‑week cycle option with the potential for outpatient or at‑home administration ^[2]. Key unanswered questions include whether the subcutaneous coformulation provides comparable clinical benefit and durability in antibody‑negative (seronegative) patients and how efgartigimod’s real‑world effectiveness and comparative performance versus other immunotherapies will perform in head‑to‑head use and across serotypes?

Dr. Vikram Patel · Neurology

The FDA approved efgartigimod alfa coformulated with hyaluronidase (VYVGART HYTRULO) for the treatment of adult patients with generalized myasthenia gravis (gMG) on 2026-05-08 based on randomized-trial evidence showing a 67.7% Myasthenia Gravis–Activities of Daily Living (MG-ADL) responder rate with efgartigimod versus 29.7% with placebo in anti‑AChR antibody–positive patients in Study 1 ^[2]. The subcutaneous coformulation demonstrated comparable pharmacodynamic effect versus the intravenous formulation and is approved with a defined subcutaneous dosing regimen ^[2].

Clinical Context

Efgartigimod alfa is an Fc fragment that targets the neonatal Fc receptor (FcRn) to reduce circulating IgG, including pathogenic autoantibodies implicated in gMG; VYVGART HYTRULO is a subcutaneous coformulation of efgartigimod alfa and hyaluronidase that increases subcutaneous tissue permeability to enable SC administration ^[2]. The FDA approval for VYVGART HYTRULO adds a subcutaneous FcRn‑blocking option for adults with gMG and is supported by randomized, placebo‑controlled data in antibody‑positive patients plus bridging pharmacodynamic evidence for the SC product ^[2]. The provided source excerpts do not report data for other agents mentioned in the request (ravulizumab, rituximab, eculizumab) or a full serotype‑based algorithm in the provided source excerpts; those items are not reported in the provided source excerpts ^[1]^[2].

Key Findings

Study 1 (anti‑AChR antibody–positive patients) showed efgartigimod alfa (intravenous formulation evaluated in the trial) achieved an MG-ADL responder rate of 67.7% versus 29.7% with placebo during the first treatment cycle (p <0.0001) ^[2].
The same study showed a QMG responder rate of 63.1% with efgartigimod versus 14.1% with placebo during the first treatment cycle (p <0.0001) ^[2].
Study 1 enrolled 167 patients randomized to efgartigimod IV 10 mg/kg (n=84) or placebo (n=83); the trial population had median baseline MG-ADL of 9 and median QMG of 16 ^[2].
The FDA labeling establishes the approved subcutaneous regimen for VYVGART HYTRULO: prefilled syringe 1,000 mg efgartigimod alfa + 10,000 units hyaluronidase administered subcutaneously once weekly for 4 weeks per treatment cycle (vial presentation: 1,008 mg / 11,200 units with similar schedule); subsequent cycles administered based on clinical evaluation ^[2]. Clinicians should consult current prescribing information for complete dosing guidance.

Safety & Tolerability

Respiratory tract infections were listed among the most common adverse reactions in the provided source excerpts ^[1]^[2].
Urinary tract infections were listed among the most common adverse reactions in the provided source excerpts ^[1]^[2].
Headache was listed among the most common adverse reactions in the provided source excerpts ^[1]^[2].
Hypersensitivity reactions, with examples of eyelid swelling, shortness of breath, and rash, have been reported with efgartigimod formulations in the provided source excerpts ^[1]^[2].
The product causes a reduction in circulating IgG; as a result, the risk of infections may increase and vaccination planning is recommended before initiating a new treatment cycle ^[2].

Study Design

The pivotal evidence supporting the approval included Study 1, a 26‑week, multicenter, randomized, double‑blind, placebo‑controlled trial (NCT03669588) that enrolled 167 adult patients and randomized them to efgartigimod IV 10 mg/kg (n=84) or placebo (n=83) ^[2]. Clinicians should consult current prescribing information for full dosing guidance. Key eligibility included MGFA Class II–IV and MG‑ADL total score ≥5; the primary efficacy outcome was MG‑ADL responder rate during the first treatment cycle, defined as ≥2‑point reduction sustained for at least 4 consecutive weeks ^[2]. VYVGART HYTRULO’s approval was supported by bridging pharmacodynamic data showing comparable effect of the SC coformulation versus the IV formulation ^[2].

FAQ

What is efgartigimod alfa (VYVGART HYTRULO) approved for?

Efgartigimod alfa coformulated with hyaluronidase (VYVGART HYTRULO) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG). The FDA labeling also lists chronic inflammatory demyelinating polyneuropathy (CIDP) among indications for the product formulation described in the prescribing information. The approval for gMG is supported by randomized controlled trial evidence in anti‑AChR antibody–positive patients.

How does efgartigimod alfa work?

Efgartigimod alfa is an engineered IgG1 fragment that binds the neonatal Fc receptor (FcRn) and inhibits FcRn‑mediated recycling of IgG, causing reductions in circulating IgG levels, including pathogenic autoantibodies such as anti‑AChR. Hyaluronidase in the coformulation transiently increases subcutaneous tissue permeability to facilitate subcutaneous administration of the FcRn blocker; the permeability effect is reversible within 24–48 hours according to the prescribing information.

What is the recommended dose of VYVGART HYTRULO?

The approved subcutaneous dosing for gMG is a prefilled syringe containing 1,000 mg efgartigimod alfa plus 10,000 units hyaluronidase administered subcutaneously once weekly for 4 weeks as a treatment cycle; a single‑dose vial presentation (1,008 mg / 11,200 units) is administered with a similar once‑weekly ×4 schedule. Subsequent cycles may be administered based on clinical evaluation. Clinicians should consult current prescribing information for complete dosing guidance.

What are the most common side effects?

The most commonly reported adverse reactions in the provided source excerpts included respiratory tract infections, headache, and urinary tract infections. The product reduces IgG levels, and the labeling advises that the risk of infections may be increased; hypersensitivity reactions (examples given include eyelid swelling, shortness of breath, and rash) have also been reported in the provided source excerpts. Vaccination status and timing should be considered before initiating new treatment cycles because of transient IgG reduction.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves Efgartigimod for gMG: 67.7% MG-ADL Response

Direct Clinical Takeaway & Evidence Summary

FDA Approves Efgartigimod for gMG: 67.7% MG-ADL Response

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Neurology in your inbox.

Related Clinical Updates

Oveporexton: Increases Wakefulness (MWT) 25.4 min in Narcolepsy Type 1

FDA Approves Leucovorin for Cerebral Folate Transport Deficiency

lecanemab and donanemab: amyloid confirmation and PET criteria for patient selection

Verified HCP Portal